Altimmune Inc. (NASDAQ: ALT) presented Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, outlining a three-front development plan for pemvidutide (an investigational once-weekly GLP-1/glucagon dual agonist peptide with FDA Breakthrough Therapy Designation for MASH). PERFORMA is the Phase 3 MASH trial with a 5-year duration and 52-week accelerated-approval look; readout is expected in 2029. RECLAIM is the Phase 2 alcohol use disorder trial reporting consistent reductions in heavy drinking days, a 2.2-level drop in WHO Risk Drinking Level, improvement in zero-heavy-drinking-days, and lower phosphatidylethanol (PEth) alcohol-consumption biomarker levels versus placebo. RESTORE is the Phase 2 alcohol-related liver disease trial that has completed enrollment and uses FibroScan liver stiffness as the primary endpoint with 12-month readout and 6-month interim. Altimmune reported $519 million in cash as of June 30, 2026, funding the MASH Phase 3 program through the 2029 readout. Pemvidutide is one of three glucagon-containing peptide candidates in late-stage MASH development alongside Boehringer-Zealand's survodutide and Lilly's retatrutide.
Kailera Therapeutics (NASDAQ: KLRA) continues through September 2026 the ramp toward global ex-China Phase 3 initiation for ribupatide (a once-weekly subcutaneous injection GIP/GLP-1/glucagon triple agonist peptide licensed globally ex-China from Hengrui Pharma under the May 2024 up-to-$5+ billion collaboration). The China Phase 3 program is complete with mean weight loss of nearly 18% at 48 weeks in Chinese overweight and obese adults. Ribupatide oral formulation (HRS-7535, licensed as KAI-7535 to Kailera ex-China) had NMPA marketing authorization applications accepted in China September 2, 2026 for both obesity and type 2 diabetes based on the OUTSTAND-1 and OUTSTAND-2 Phase 3 trials. The global ex-China ribupatide Phase 3 program is designed to run against Eli Lilly's retatrutide (28.3% weight loss in TRIUMPH-1) as the second-in-class triple-agonist option, and Kailera has signaled ambition to file in the U.S. within 12-18 months of Phase 3 readout. Ribupatide would be the third Chinese-origin GLP-1-class asset to reach U.S. clinical development, following Innovent-Lilly mazdutide and Sciwind-Pfizer ecnoglutide.
Boehringer Ingelheim continues enrollment through September 2026 in the Phase 2 clinical trial of BI 3034701 (a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist), which the company initiated in July 2026 as part of the expanded obesity pipeline anchored on survodutide (dual GLP-1/glucagon agonist, in Phase 3 MASH with Zealand Pharma partnership). BI 3034701 was discovered via the Boehringer-Gubra Biopharmaceutical peptide discovery collaboration and is designed to engage the NPY2 receptor alongside GLP-1 and GIP receptors — a differentiated triple-target mechanism versus Eli Lilly's retatrutide (GIP/GLP-1/glucagon) and Hengrui's ribupatide (GIP/GLP-1/glucagon). The NPY2 receptor pathway is involved in central appetite regulation and has been targeted historically by hormones including PYY(3-36); Boehringer positions BI 3034701 as engaging appetite regulation through a complementary mechanism to the incretin axis. Phase 2 readout timing has not been publicly disclosed. Boehringer Ingelheim's overall obesity pipeline positions the company as a distant third-place challenger to Eli Lilly and Novo Nordisk with survodutide, BI 3034701, and the emerging GLP-1/glucagon dual agonist program.